PH-804 TME / Phio Pharma - LARVOL DELTA

Phio Announces Data Showcasing INTASYL’s Role in Helping Immune Cells Target and Kill Cancer Cells (Phio Pharma Press Release) - "Phio Pharmaceuticals Corp....today announced that it is presenting data about its proprietary INTASYL platform and INTASYL compounds....INTASYL compound PH-762 silences PD-1, improving therapeutic efficacy in vivo. The PH-894 compound precisely silences BRD4 to enhance tumor cell immunogenicity and induce apoptosis. Silencing TIGIT in NK cells, using compound PH-804, enhances their activation, cytokine release, and target cell killing. The PH-905 compound silences CBLB, increasing NK cell cytotoxicity and proliferation....The data is being presented on October 8th at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal."

Preclinical • Oncology

INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer. (PubMed, Cancer Immunol Immunother) - "Delivering PH-804 to NK cells before ACT has emerged as a promising strategy to counter TIGIT inhibition, thereby improving the antitumor response. This approach offers the potential for more potent off-the-shelf products for adoptive cell therapy, particularly for hematological malignancies."

IO biomarker • Journal • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Oncology • TIGIT

PH-804, an INTASYL self-delivering RNAi compound that targets TIGIT enhances NK cell cytotoxicity to tumor cells (SITC 2022) - "Conclusions Here, we demonstrate the potential of PH-804 to improve NK cell potency in ACT. By treating NK cells with INTASYL targeting the inhibitory receptor TIGIT ex vivo, during NK cell expansion, the anti-tumor response of these cells was enhanced potentially resulting in a more effective cell therapy for solid tumors and hematological malignancies."

IO biomarker • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • IL2 • NCAM1 • TIGIT

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PRNewswire) - "Phio Pharmaceuticals...announced it is scheduled to provide an update on its programs at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Boston, MA from November 8 - 12, 2022. This will include an update on its first-in-human clinical trial with PH-762 in advanced melanoma; data demonstrating the potential of PH-762 to further enhance the function of tumor infiltrating lymphocytes (TILs) with its partner AgonOx, Inc.; and new preclinical data on relevant targets identified in cancer immunotherapy using our INTASYL compounds."

P1 data • Preclinical • Breast Cancer • Melanoma • Oncology • Skin Cancer • Solid Tumor

"PH-804 from PHIO preclinicl" (@DebarJohn)

[VIRTUAL] Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer (SITC 2020) - "Here we demonstrate the in vivo efficacy of INTASYL specifically targeting TIGIT (PH-804), PD-1 (PH-762), PD-L1 (PH-790) alone or in combination in a CT26 model of murine colorectal carcinoma...All treatments were well tolerated. Conclusions n/a"

IO Biomarker • Monotherapy • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

[VIRTUAL] Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer (SITC 2020) - "Here we demonstrate the in vivo efficacy of INTASYL specifically targeting TIGIT (PH-804), PD-1 (PH-762), PD-L1 (PH-790) alone or in combination in a CT26 model of murine colorectal carcinoma...All treatments were well tolerated. Conclusions n/a"

IO Biomarker • Monotherapy • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

[VIRTUAL] Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment (AACR-II 2020) - "Previously, we have shown the ability of our INTASYL self-delivering RNAi technology to target PD-1 (PH-762) and TIGIT (PH-804) in human immune cells...In vivo, mPH-804 intratumoral injection targets TIGIT, overcomes the immunosuppressive microenvironment, enhances effector T cell function and inhibits tumor growth. Together, these novel findings support the hypothesis that local TIGIT silencing is a viable approach to regain T cell effector function and tumor cell kill which warrants further investigation in patients."

Biomarker • IO Biomarker • Tumor microenvironment • Oncology • CD8 • IL2RA

Phio presents additional data supporting potential of TIGIT targeting INTASYL compound in the tumor microenvironment at AACR 2020 (PRNewswire) - "In an in vivo study, tumor growth inhibition was determined for both PH-804 and an anti-TIGIT antibody in colorectal carcinoma tumor bearing mice. Results from the study demonstrated that our INTASYL compound was efficiently delivered intratumorally to immune cells, resulting in a dose dependent inhibition of tumor growth, reaching statistical significance levels for PH-804 and anti-TIGIT antibody treatment arms...In addition, analysis of the TME of the PH-804 treated mice showed a dose dependent increase in cytotoxic effector T cells, and a dose dependent activation of such T cells as shown by the expression of activation makers such as CD25 and CD69."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Phio announces positive in vivo data on the intratumoral use of INTASYL compounds showing strong antitumor activity (PRNewswire) - "Phio Pharmaceuticals Corp...announced positive data from in vivo studies that show strong antitumoral efficacy with several of its INTASYL pipeline programs, including PH-762, PH-894 and PH-804. These results show that intratumoral delivery of INTASYL compounds inhibited tumor growth by overcoming the immunosuppressive tumor microenvironment (TME) as shown by changes in T cell composition and activation. Therefore, the Company believes these pipeline programs show great promise in the treatment of solid tumors. These data were presented during the ASCO 2020 Virtual Scientific Program."

Preclinical • Oncology

Newly added product (RXi Pharma Press Release) - Preclinical, Oncology

Pipeline update • Oncology

Phio Pharmaceuticals reports second quarter 2019 financial results and provides business update (PRNewswire) - “Pipeline Advancements: Based on these positive preclinical results, Phio is advancing PH-762 for two distinct clinical applications…The Company expects to start clinical studies for both of these pipeline products based on PH-762 in 2020….PH-804, is designed to silence the expression of immune exhaustion target TIGIT by NK cells…The Company plans to enter the clinic with PH-804 in the second half of 2020….We expect to advance additional sd-rxRNA candidates into preclinical and clinical development in the second half of 2019.”

New trial • Preclinical